Patents Assigned to Merz Pharma GmbH & Co. KGAA
-
Patent number: 11952601Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting an increased duration of effect without a delayed onset of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a domain consisting of proline, alanine, serine, threonine, glycine and glutamate residues, and the methods comprise the steps of inserting a nucleic acid sequence coding for said domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising said domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with an increased duration of effect without a delayed onset of effect.Type: GrantFiled: June 20, 2017Date of Patent: April 9, 2024Assignee: MERZ PHARMA GMBH & CO. KGAAInventors: Fred Hofmann, Marcel Jurk, Manuela López De La Paz, Daniel Scheps, Jürgen Frevert
-
Patent number: 11819664Abstract: The present invention generally relates to a mixing nozzle (12) for mixing at least two liquid compositions such as a first liquid composition and a second liquid composition. The mixing nozzle (10) is configured to be coupled to a body (11) of a multi-component application device (10), in particular to a body (11) of a two-component syringe assembly, for injection of a liquid composition, which body (11) is configured to separately store said at least two solutions. The present invention further relates to a multi-component application device (10) comprising said mixing nozzle (12) and to a kit comprising said mixing nozzle (12) or said application device (10). Furthermore, the present invention relates to a method using said application device or said kit, for example for replacing or filling a biological tissue or increasing the volume of a biological tissue.Type: GrantFiled: June 13, 2018Date of Patent: November 21, 2023Assignee: MERZ PHARMA GMBH & CO. KGAAInventors: Franck Villain, Uwe Wortmann, Norbert Kaspers, Johannes Egger, Thomas Sowden Reinhold, Guido Popp, Michael Kunz, Jonathan Mason
-
Publication number: 20230277432Abstract: A liquid composition for improving the facial contour and shape of the human or animal face by injection, the liquid composition comprising water and at least one of the following components A, B and C: at least one component A, which leads to an osmotic concentration in the range from 500 to 5000 mOsm in the liquid composition, at least one high viscosity component B, which leads to a viscosity of the liquid composition in the range from 10 to 1500 mPas, at least one micro-particles component C, comprising micro-particles with an average particle size not larger than 0.25 mm, preferably in the range of 0.001 mm to 0.25 mm, and optionally comprising a local anesthetic compound D.Type: ApplicationFiled: March 3, 2023Publication date: September 7, 2023Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Sabine OTTO, Rainer POOTH, Benjamin HAGEDORN
-
Patent number: 11672750Abstract: The present invention relates to a dermal filler composition based on crosslinked hyaluronic acid, calcium phosphate material particles and carboxymethyl cellulose. The present invention further provides a process for preparing said dermal filler composition, and its use in cosmetic treatments such as for improvement of skin quality.Type: GrantFiled: April 12, 2019Date of Patent: June 13, 2023Assignee: MERZ PHARMA GMBH & CO. KGAAInventors: Roland Stragies, Nadine Hagedorn, Lubin Belkovi
-
Patent number: 11529398Abstract: This invention relates to improved uses of botulinum neurotoxins in the treatment of sialorrhea or diseases or conditions relating to increased saliva production. In particular are botulinum neurotoxins disclosed which are administered into parotid and submandibular glands in a dose ratio between 1.45 to 1 and 1.7 to 1.Type: GrantFiled: June 5, 2020Date of Patent: December 20, 2022Assignee: MERZ PHARMA GMBH & CO. KGAAInventors: Janos Csikos, Irena Pulte, Michael Althaus, Markus Krueer, Nico Wegener
-
Patent number: 11382960Abstract: The present invention relates to methods for treating diseases and disorders by administering a composition containing the neurotoxic component of a Clostridium botulinum toxin complex, wherein the composition is devoid of any other protein of the Clostridium botulinum toxin complex and wherein the composition is administered at short intervals and/or in high doses.Type: GrantFiled: September 1, 2020Date of Patent: July 12, 2022Assignee: MERZ PHARMA GmbH & CO. KGaAInventors: Matthias Marx, Susanne Grafe, Reiner Benecke, Dirk Dressler
-
Patent number: 11357821Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a random coil domain, and the methods comprise the steps of inserting a nucleic acid sequence coding for a random coil domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising the random coil domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with increased duration of effect.Type: GrantFiled: December 9, 2019Date of Patent: June 14, 2022Assignee: MERZ PHARMA GMBH & CO. KGAAInventors: Juergen Frevert, Fred Hofmann, Michael Schmidt, Manuela López De La Paz, Daniel Scheps
-
Patent number: 11344573Abstract: The present invention generally relates to the treatment of gynoid lipodystrophy, and more specifically to the use of calcium (hydroxy)phosphate particles in combination with at least one compound capable of reducing local subcutaneous fat in the treatment of gynoid lipodystrophy.Type: GrantFiled: October 24, 2017Date of Patent: May 31, 2022Assignee: MERZ PHARMA GMBH & CO. KGAAInventors: Harry Frank Abst, Rainer Pooth, Martina Kerscher, Thomas Hengl, Birgit Blessmann-Gurk, Sabine Otto
-
Patent number: 11331434Abstract: The present invention relates a botulinum toxin prefilled syringe system with desirable injection force characteristics, in particular low gliding force and low break loose force, comprising a syringe barrel of glass containing a liquid botulinum toxin composition, a plunger stopper and a closure device such as a tip cap or a needle shield. In addition, the present invention relates to a kit comprising the botulinum toxin prefilled syringe system, and optionally instructions for use, and to the use of the botulinum toxin prefilled syringe system in therapeutic and cosmetic applications.Type: GrantFiled: June 20, 2017Date of Patent: May 17, 2022Assignee: MERZ PHARMA GMBH & CO. KGAAInventor: Markus Vogt
-
Patent number: 11324672Abstract: The present invention generally relates to the field of hyaluronic acid (HA) dermal fillers, and more specifically to methods for preparing crosslinked HA-based compositions in the form of a gel comprising high-temperature dialysis and/or crosslinking in the presence of phosphate and an alkaline metal halide salt. The present invention further relates to crosslinked HA-based gel compositions prepared by said methods and their use as dermal fillers in aesthetic applications such as wrinkle treatments.Type: GrantFiled: November 2, 2017Date of Patent: May 10, 2022Assignee: Merz Pharma GmbH & Co. KGaAInventors: Nadine Hagedorn, Roland Stragies, Lubin Belkovi, Radia El-Banna
-
Publication number: 20220010294Abstract: This invention relates to novel recombinant botulinum neurotoxins serotype A exhibiting both (i) an increased duration of effect and (ii) a high specific biological activity. These novel recombinant botulinum neurotoxins comprise at least two additional domains consisting of proline, alanine and an additional amino acid residue and at least one amino acid modification which is located at the alpha-exosite or at the beta-exosite of the light chain of the neurotoxin. The invention further relates to novel recombinant single-chain precursor botulinum neurotoxins and compositions comprising the recombinant botulinum neurotoxin with an increased duration of effect and a high specific biological activity.Type: ApplicationFiled: September 23, 2021Publication date: January 13, 2022Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Jürgen FREVERT, Fred HOFMANN, Marcel JURK, Manuela LÓPEZ DE LA PAZ, Daniel SCHEPS
-
Patent number: 11219717Abstract: The present invention relates to a prefilled plastic container, such as a plastic syringe, comprising an aqueous botulinum toxin formulation. The aqueous botulinum toxin formulation in the prefilled plastic container is stable for a prolonged time period. Furthermore, the present invention relates to a kit comprising the prefilled plastic container, and to the use of the prefilled plastic container for therapeutic and cosmetic purposes.Type: GrantFiled: July 1, 2019Date of Patent: January 11, 2022Assignee: Merz Pharma GmbH & Co. KGaAInventor: Markus Vogt
-
Patent number: 11208501Abstract: The present invention relates to a process for depleting epoxide species in epoxy-crosslinked polysaccharide gel compositions. In addition, the present invention relates to crosslinked polysaccharide gel compositions made by said process and their use in cosmetic and therapeutic applications.Type: GrantFiled: October 31, 2016Date of Patent: December 28, 2021Assignee: Merz Pharma GmbH & Co. KGaAInventors: Ulrich Abel, Andreas Krause
-
Patent number: 11167090Abstract: The present invention relates to a prefilled glass container, such as a prefilled glass syringe, comprising an aqueous botulinum toxin formulation. The aqueous botulinum toxin formulation in the prefilled container is stable at low to ambient temperature for a prolonged time period. Furthermore, the present invention relates to a kit comprising the botulinum toxin prefilled container, and to the use of the botulinum toxin prefilled container in therapeutic and cosmetic applications.Type: GrantFiled: December 18, 2019Date of Patent: November 9, 2021Assignee: Merz Pharma GmbH & Co. KGaAInventor: Markus Vogt
-
Patent number: 11155802Abstract: This invention relates to novel recombinant botulinum neurotoxins serotype A exhibiting both (i) an increased duration of effect and (ii) a high specific biological activity. These novel recombinant botulinum neurotoxins comprise at least two additional domains consisting of proline, alanine and an additional amino acid residue and at least one amino acid modification which is located at the alpha-exosite or at the beta-exosite of the light chain of the neurotoxin. The invention further relates to novel recombinant single-chain precursor botulinum neurotoxins and compositions comprising the recombinant botulinum neurotoxin with an increased duration of effect and a high specific biological activity.Type: GrantFiled: July 6, 2017Date of Patent: October 26, 2021Assignee: MERZ PHARMA GMBH & CO. KGAAInventors: Jürgen Frevert, Fred Hofmann, Marcel Jurk, Manuela López De La Paz, Daniel Scheps
-
Patent number: 11078472Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise (i) at least two random coil domains, or (ii) at least two domains having a polyproline II helix conformation, and the methods comprise the steps of inserting at least two nucleic acid sequences each coding for (i) a random coil domain, or (ii) a domain having a polyproline II helix conformation, into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising (i) the random coil domain-coding sequences, or (ii) the sequences encoding the domains having a polyproline II helix conformation in a host cell.Type: GrantFiled: January 19, 2017Date of Patent: August 3, 2021Assignee: Merz Pharma GmbH & Co., KGaAInventors: Fred Hofmann, Marcel Jurk, Manuela López De La Paz, Daniel Scheps, Jürgen Frevert
-
Patent number: D973871Type: GrantFiled: March 3, 2021Date of Patent: December 27, 2022Assignee: Merz Pharma GMBH & CO. KGAAInventors: Dany Borowek, Kai Tiesberger, Sophie Costiou Charretour
-
Patent number: D973872Type: GrantFiled: March 3, 2021Date of Patent: December 27, 2022Assignee: MERZ PHARMA GMBH & CO. KGAAInventors: Dany Borowek, Kai Tiesberger, Sophie Costiou Charretour
-
Patent number: D1013866Type: GrantFiled: September 29, 2021Date of Patent: February 6, 2024Assignee: Merz Pharma GmbH & Co. KGaAInventors: Dany Borowek, Sophie Costiou Charretour, Kai Tiesberger
-
Patent number: D1013867Type: GrantFiled: September 29, 2021Date of Patent: February 6, 2024Assignee: Merz Pharma GmbH & Co. KGaAInventors: Dany Borowek, Sophie Costiou Charretour, Kai Tiesberger